Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Insulin initiation in Type 2 diabetes: the implications of the 4-T study.

Diabetic medicine : a journal of the British Diabetic Association

Holt RI.
PMID: 20121882
Diabet Med. 2010 Jan;27(1):1-3. doi: 10.1111/j.1464-5491.2009.02910.x.

No abstract available.

Cite
Holt RI. Insulin initiation in Type 2 diabetes: the implications of the 4-T study. Diabet Med. 2010;27(1):1-3doi: 10.1111/j.1464-5491.2009.02910.x.
Holt, R. I. (2010). Insulin initiation in Type 2 diabetes: the implications of the 4-T study. Diabetic medicine : a journal of the British Diabetic Association, 27(1), 1-3. https://doi.org/10.1111/j.1464-5491.2009.02910.x
Holt, R I G. "Insulin initiation in Type 2 diabetes: the implications of the 4-T study." Diabetic medicine : a journal of the British Diabetic Association vol. 27,1 (2010): 1-3. doi: https://doi.org/10.1111/j.1464-5491.2009.02910.x
Holt RI. Insulin initiation in Type 2 diabetes: the implications of the 4-T study. Diabet Med. 2010 Jan;27(1):1-3. doi: 10.1111/j.1464-5491.2009.02910.x. PMID: 20121882.
Copy Download .nbib Format: NLM
Preparation and characterization of a fully iodinated insulin derivative.

The Journal of biological chemistry

GRUEN L, LASKOWSKI M, SCHERAGA HA.
PMID: 13673012
J Biol Chem. 1959 Aug;234(8):2050-3.

No abstract available.

Cite
GRUEN L, LASKOWSKI M, SCHERAGA HA. Preparation and characterization of a fully iodinated insulin derivative. J Biol Chem. 1959;234(8):2050-3
GRUEN, L., LASKOWSKI, M., & SCHERAGA, H. A. (1959). Preparation and characterization of a fully iodinated insulin derivative. The Journal of biological chemistry, 234(8), 2050-3.
GRUEN, L, et al. "Preparation and characterization of a fully iodinated insulin derivative." The Journal of biological chemistry vol. 234,8 (1959): 2050-3.
GRUEN L, LASKOWSKI M, SCHERAGA HA. Preparation and characterization of a fully iodinated insulin derivative. J Biol Chem. 1959 Aug;234(8):2050-3. PMID: 13673012.
Copy Download .nbib Format: NLM
Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.

Clinical therapeutics

Tibaldi JM.
PMID: 22030443
Clin Ther. 2011 Nov;33(11):1630-42. doi: 10.1016/j.clinthera.2011.09.019. Epub 2011 Oct 26.

BACKGROUND: As the diabetes epidemic expands, health care providers need more options to achieve glycemic control. Insulin analogue premixes provide basal and prandial insulin with 1 injection.OBJECTIVES: The aim of this review was to provide an overview of the...

Cite
Tibaldi JM. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther. 2011;33(11):1630-42doi: 10.1016/j.clinthera.2011.09.019.
Tibaldi, J. M. (2011). Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clinical therapeutics, 33(11), 1630-42. https://doi.org/10.1016/j.clinthera.2011.09.019
Tibaldi, Joseph M. "Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes." Clinical therapeutics vol. 33,11 (2011): 1630-42. doi: https://doi.org/10.1016/j.clinthera.2011.09.019
Tibaldi JM. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther. 2011 Nov;33(11):1630-42. doi: 10.1016/j.clinthera.2011.09.019. Epub 2011 Oct 26. PMID: 22030443.
Copy Download .nbib Format: NLM
Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes.

Diabetes & metabolism

Monnier L, Colette C, Owens D.
PMID: 25459321
Diabetes Metab. 2014 Dec;40(6):483-4. doi: 10.1016/j.diabet.2014.10.001.

No abstract available.

Cite
Monnier L, Colette C, Owens D. Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes. Diabetes Metab. 2014;40(6):483-4doi: 10.1016/j.diabet.2014.10.001.
Monnier, L., Colette, C., & Owens, D. (2014). Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes. Diabetes & metabolism, 40(6), 483-4. https://doi.org/10.1016/j.diabet.2014.10.001
Monnier, L, et al. "Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes." Diabetes & metabolism vol. 40,6 (2014): 483-4. doi: https://doi.org/10.1016/j.diabet.2014.10.001
Monnier L, Colette C, Owens D. Acylated-based long-acting insulin analogues: is “misfolding” the problem? Commentary letter on Hamasaki H and Yanai H. The switching from insulin glargine to insulin degludec reduced HbA1c, daily insulin doses and anti-insulin antibody in anti-insulin antibody-positive subjects with type 1 diabetes. Diabetes Metab. 2014 Dec;40(6):483-4. doi: 10.1016/j.diabet.2014.10.001. PMID: 25459321.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries